Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma | Zendy

Koji Matsuo | Zendy; Kazuhiro Tanabe | Zendy; Masae Ikeda | Zendy; Takeo Shibata | Zendy; Hiroshi Kajiwara | Zendy; Masaki Miyazawa | Zendy; Mariko Miyazawa | Zendy; Masaru Hayashi | Zendy; Masako Shida | Zendy; Takeshi Hirasawa | Zendy; Lynda D. Roman | Zendy; Mikio Mikami | Zendy

Open Access

Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma

Author(s) -

Koji Matsuo,

Kazuhiro Tanabe,

Masae Ikeda,

Takeo Shibata,

Hiroshi Kajiwara,

Masaki Miyazawa,

Mariko Miyazawa,

Masaru Hayashi,

Masako Shida,

Takeshi Hirasawa,

Lynda D. Roman,

Mikio Mikami

Publication year - 2018

Publication title -

archives of gynecology and obstetrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.793

H-Index - 68

eISSN - 1432-0711

pISSN - 0932-0067

DOI - 10.1007/s00404-018-4658-z

Subject(s) - medicine , hazard ratio , biomarker , serous fluid , ovarian cancer , stage (stratigraphy) , gastroenterology , confidence interval , oncology , carcinoma , serous carcinoma , cancer , paleontology , biochemistry , chemistry , biology

Fully sialylated alpha-chain of complement 4-binding protein (A2160) is a member of the glycoprotein family and has recently been identified as a diagnostic biomarker for epithelial ovarian cancer. This study examined the utility of A2160 as a prognostic biomarker for this disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research